Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.06) per share and revenue of $7.41 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Entrada Therapeutics Trading Up 1.7%

Entrada Therapeutics stock opened at $11.48 on Wednesday. The stock has a fifty day moving average price of $10.83 and a 200 day moving average price of $8.35. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $13.17. The firm has a market capitalization of $438.77 million, a P/E ratio of -4.61 and a beta of -0.12.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TRDA. Wellington Management Group LLP increased its stake in Entrada Therapeutics by 9.5% during the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after buying an additional 90,339 shares during the period. Millennium Management LLC lifted its stake in shares of Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after acquiring an additional 666,287 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after acquiring an additional 42,479 shares in the last quarter. State Street Corp boosted its holdings in Entrada Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after purchasing an additional 10,174 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in Entrada Therapeutics by 14.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 362,786 shares of the company’s stock valued at $3,729,000 after purchasing an additional 46,976 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TRDA. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Oppenheimer started coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Roth Mkm set a $13.00 price target on Entrada Therapeutics in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.